IMMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 33 cases where IMMP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for IMMP just turned positive on October 20, 2026. Looking at past instances where IMMP's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Following a +3.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMP advanced for three days, in 213 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for IMMP entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.568) is normal, around the industry mean (2.973). P/E Ratio (-0.293) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. IMMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LIMN advanced for three days, in 50 of 88 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for LIMN just turned positive on September 22, 2026. Looking at past instances where LIMN's MACD turned positive, the stock continued to rise in 22 of 49 cases over the following month. The odds of a continued upward trend are 45%.
LIMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LIMN as a result. In 33 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 31%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for LIMN entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.896) is normal, around the industry mean (2.973). P/E Ratio (-0.130) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. LIMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IMMP | ||
|---|---|---|
OUTLOOK RATING 1..100 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 95 | |
P/E GROWTH RATING 1..100 | 8 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| IMMP | LIMN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 87% | N/A |
| Stochastic ODDS (%) | N/A | 1 day ago 52% |
| Momentum ODDS (%) | N/A | 1 day ago 31% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 45% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 46% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 53% |
| Advances ODDS (%) | 2 days ago 83% | 3 days ago 57% |
| Declines ODDS (%) | 8 days ago 84% | 1 day ago 73% |
| BollingerBands ODDS (%) | 3 days ago 90% | 1 day ago 50% |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 53% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMMP’s FA Score shows that 1 FA rating(s) are green while LIMN’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMMP’s TA Score shows that 4 TA indicator(s) are bullish while LIMN’s TA Score has 4 bullish TA indicator(s).
IMMP (@Biotechnology) experienced а -2.96% price change this week, while LIMN (@Biotechnology) price change was -4.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
IMMP is expected to report earnings on Dec 02, 2026.
LIMN is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, IMMP has been loosely correlated with TBPH. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IMMP jumps, then TBPH could also see price increases.
| Ticker / NAME | Correlation To IMMP | 1D Price Change % | ||
|---|---|---|---|---|
| IMMP | 100% | -3.66% | ||
| TBPH - IMMP | 60% Loosely correlated | N/A | ||
| ELOX - IMMP | 47% Loosely correlated | -1.13% | ||
| GPCR - IMMP | 38% Loosely correlated | -0.36% | ||
| BCRX - IMMP | 38% Loosely correlated | +0.39% | ||
| HIND - IMMP | 36% Loosely correlated | -2.17% | ||
More | ||||
A.I.dvisor indicates that over the last year, LIMN has been loosely correlated with FTH. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if LIMN jumps, then FTH could also see price increases.
| Ticker / NAME | Correlation To LIMN | 1D Price Change % | ||
|---|---|---|---|---|
| LIMN | 100% | -0.32% | ||
| FTH - LIMN | 35% Loosely correlated | -2.28% | ||
| UPB - LIMN | 35% Loosely correlated | +6.79% | ||
| IMMP - LIMN | 34% Loosely correlated | -3.66% | ||
| RNA - LIMN | 32% Poorly correlated | +2.00% | ||
| ALDX - LIMN | 31% Poorly correlated | -3.73% | ||
More | ||||